Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses.

Tioconazole is a substituted imidazole antimicrobial agent structurally related to other drugs in this group. It has been shown to have a broad spectrum of activity in vitro against dermatophytes and yeasts, as well as against some chlamydia, trichomonads and Gram-positive bacteria. Both open and controlled clinical trials have clearly demonstrated the efficacy and safety of topical preparations of tioconazole for treating superficial dermatophyte or yeast infections of the skin and vaginal candidiasis. In comparative studies it was at least as effective as alternative imidazole antifungal drugs, and in a few trials significantly greater efficacy has been reported for tioconazole, compared with clotrimazole, miconazole, econazole and systemic ketoconazole. Preliminary studies in other clinical areas suggest tioconazole may be useful for treating onychomycosis (in a special nail formulation), napkin-rash due to Candida albicans, impetigo, and vaginal trichomoniasis, although comparative studies are needed in each of these settings to clearly assess its relative place in therapy. Thus, tioconazole is an effective and well tolerated treatment for vaginal candidiasis and superficial fungal infections of the skin.

[1]  G. Ehlers,et al.  A Comparison of Bifonazole and Ciclopiroxolamine: In Vitro, Animal, and Clinical Studies./Bifonazol und Ciclopiroxolamin im Vergleich: In vitroStudien, Tierversuche und klinische Untersuchungen , 1988, Mycoses.

[2]  R. Hay,et al.  The topical treatment of onychomycosis using a new combined urea/imidazole preparation , 1988, Clinical and experimental dermatology.

[3]  D. Wheatley,et al.  Tinea infections treated with bifonazole gel. , 1988, Mycoses.

[4]  F. Soyinka.  Bifonazole in the treatment of fungal skin infections in the tropics: a clinical and mycological study. , 1987, Current medical research and opinion.

[5]  S. López Gómez,et al.  Short course bifonazole therapy in pityriasis versicolor. , 1987, Clinical and experimental dermatology.

[6]  E. Tschen,et al.  Treatment of interdigital tinea pedis and tinea (pityriasis) versicolor with bifonazole 1% solution applied once daily , 1986 .

[7]  E. Hernández-Pérez.  A comparison between one and two weeks' treatment with bifonazole in pityriasis versicolor. , 1986, Journal of the American Academy of Dermatology.

[8]  M. Richardson,et al.  Bifonazole Gel in the Treatment of Seborrhoeic Eczema , 1986 .

[9]  J. Lalosevic,et al.  Double-Blind Comparative Trial of Three New Antifungal Cream Formulations in Superficial Candidosis , 1986 .

[10]  E. Difonzo,et al.  Bifonazole in the Treatment of Dermatomycoses: Results of a Multicentric Study in Italy , 1986 .

[11]  A. Oriani,et al.  Preliminary Therapeutic Results in Onychomycosis with a Special Formulation , 1986 .

[12]  F. Saffé.  Bifonazole in Dermatological Practice: Results of a Multicentre Study , 1986 .

[13]  H. Döring.  Experience Gained with Topical Therapy with Bifonazole in Unusual Indications , 1986 .

[14]  L. Bonito,et al.  The Use of Bifonazole in the First 2 Years of Life , 1986 .

[15]  J. Lalosevic,et al.  Results of a New Therapeutic Regimen in the Treatment of Onychomycosis , 1986 .

[16]  H. Tronnier,et al.  Investigations into the Anti-inflammatory Effect of Bifonazole , 1986 .

[17]  R. Ashton.  Comparative Clinical Trial: Bifonazole vs Miconazole in Dermatomycosis , 1986 .

[18]  D. Earl,et al.  Bifonazole 1% gel in the treatment of superficial dermatophytoses and erythrasma of the feet and groin. , 1986, Pharmatherapeutica.

[19]  J. Gentles,et al.  A comparative study of once daily bifonazole cream versus twice daily miconazole cream in the treatment of tinea pedis. , 2009, Mykosen.

[20]  E. Houang,et al.  Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule , 1985, Antimicrobial Agents and Chemotherapy.

[21]  Y. Clayton,et al.  Tioconazole nail solution—an open study of its efficacy in onychomycosis , 1985, Clinical and experimental dermatology.

[22]  D. Gibbs,et al.  A Comparative Study of Once versus Twice Daily Treatment of Superficial Dermatophyte and Yeast Infections with Tioconazole (1%) Cream , 1985, The Journal of international medical research.

[23]  E. Okafor,et al.  Tioconazole in dermatophyte infections , 1985 .

[24]  I. Itam.  Tioconazole in vaginal candidiasis: an open evaluation of two formulations in St. Margaret maternity hospital, Calabar , 1985 .

[25]  H. Silva,et al.  Evaluation of tioconazole in the treatment of vaginal trichomoniasis , 1985 .

[26]  B. Osinusi,et al.  Tioconazole 6Ξ vaginal ointment as a single dose treatment of vaginal candidiasis , 1985 .

[27]  R. Negroni,et al.  Treatment of tinea corporis or tinea cruris with bifonazole 1% gel: an open, multicentre study. , 1985, Pharmatherapeutica.

[28]  R. Negroni,et al.  Treatment of superficial candidiasis with bifonazole 1% gel. , 1985, Pharmatherapeutica.

[29]  R. Negroni,et al.  An open, multicentre assessment of the effectiveness of bifonazole in the treatment of tinea (pityriasis) versicolor. , 1985, Pharmatherapeutica.

[30]  Darl E. Vander Ploec,et al.  A new topical antifungal drug: tioconazole. , 1984 .

[31]  P. Farr,et al.  The response of seborrhoeic dermatitis to ketoconazole , 1984, The British journal of dermatology.

[32]  H. Rohde-Werner.  Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis. , 1984, Journal of International Medical Research.

[33]  F. Odds,et al.  Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. , 1984, The Journal of antimicrobial chemotherapy.

[34]  D. Berg,et al.  Reduction of the in vivo virulence of Candida albicans by pretreatment with subinhibitory azole concentrations in vitro. , 1984, Dermatologica.

[35]  A. Grigoriu,et al.  Die genito‐glutaeale Candidosis des Kleinkindes Behandlung mit Trosyd (tioconazol) , 1984 .

[36]  D. Stevens,et al.  Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use , 1984, Antimicrobial Agents and Chemotherapy.

[37]  S. Gorman,et al.  The effect of imidazoles on germination of arthrospores and microconidia of Trichophyton mentagrophytes. , 1984, The Journal of antimicrobial chemotherapy.

[38]  H. Döring.  Treatment of Sebopsoriasis , 1984 .

[39]  J. Lalosevic,et al.  Bifonazole cream in the treatment of superficial candidosis. A double-blind comparative study. , 1984, Dermatologica.

[40]  W. Kukovetz,et al.  Retention time and concentration in human skin of bifonazole and clotrimazole. , 1984, Dermatologica.

[41]  H. Yamaguchi,et al.  In vivo activity of bifonazole in guinea pigs: its characteristic features and comparison with clotrimazole. , 1984, Dermatologica.

[42]  A. Chu.  Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. , 1984, Dermatologica.

[43]  F. Odds,et al.  Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro. , 1984, The Journal of antimicrobial chemotherapy.

[44]  M. Osumi,et al.  The effect of bifonazole on the structure of Trichophyton mentagrophytes. , 1984, Dermatologica.

[45]  E. Hernández-Pérez.  Bifonazole cream: once-a-day application every second day in tinea cruris and tinea corporis. , 1984, Dermatologica.

[46]  R. Negroni,et al.  Prophylaxis of tinea pedis interdigitalis with bifonazole, 1% powder. , 1984, Dermatologica.

[47]  S. Nolting.  Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. , 1984, Dermatologica.

[48]  D. Berg,et al.  Bifonazole, a biochemist's view. , 1984, Dermatologica.

[49]  L. Gip.  Bifonazole: patch-test trials on local tolerance. , 1984, Dermatologica.

[50]  D. Berg,et al.  Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. , 1984, Arzneimittel-Forschung.

[51]  A. Espinel-Ingroff,et al.  In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. , 1984, Sabouraudia.

[52]  N. Falser.  Fungal infection of the ear. Etiology and therapy with bifonazole cream or solution. , 1984, Dermatologica.

[53]  R. Mora,et al.  Comparative efficacy and tolerance of 1% bifonazole cream and bifonazole cream vehicle in patients with tinea versicolor. , 1984, Dermatologica.

[54]  E. Johnson,et al.  Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans. , 1983, The Journal of antimicrobial chemotherapy.

[55]  C. Yoffe,et al.  Short-term treatment of Trichomonas vaginalis with tioconazole cream, a new antifungal agent. , 1983, Gynäkologisch-Geburtshilfliche Rundschau.

[56]  A. Vinnerberg,et al.  Open comparison of the efficacy, toleration and safety of tioconazole and econazole in the 3-day treatment of vaginal candidiasis. , 1983, Gynakologische Rundschau.

[57]  J. Cohen.  Open comparison of the efficacy, toleration and safety of tioconazole cream and econazole ovules used in the 3-day treatment of patients with vaginal candidiasis. , 1983, Gynakologische Rundschau.

[58]  J. Artner,et al.  Open studies of the efficacy, tolerance, systemic absorption and vaginal persistence following a single application of tioconazole ointment in the treatment of patients with vaginal candidiasis. , 1983, Gynakologische Rundschau.

[59]  H. Yamaguchi,et al.  In-vitro studies of a new oral azole antimycotic, BAY N 7133. , 1983, The Journal of antimicrobial chemotherapy.

[60]  W. Neilson,et al.  Tioconazole in the Treatment of Vaginal Candidiasis , 1983 .

[61]  M. Tarbit,et al.  Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties. , 1983, Dermatologica.

[62]  R. Oittner.  Open comparison of the efficacy, toleration and safety of tioconazole cream used for either 3- or 6-day treatment of patients with vaginal candidiasis. , 1983, Gynäkologisch-Geburtshilfliche Rundschau.

[63]  S. Jevons,et al.  Tioconazole in the treatment of fungal infections of the skin. An international clinical research program. , 1983, Dermatologica.

[64]  G. Angelini,et al.  Efficacy and safety of bifonazole (BAY h 4502) in patients with pityriasis versicolor and tinea cruris. , 1983, Mykosen.

[65]  S. Stettendorf.  Tolerability and efficacy of bifonazole in dermatomycoses. , 1983, Arzneimittel-Forschung.

[66]  D. Grigoriu,et al.  Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. , 1983, Dermatologica.

[67]  T. Fredriksson.  Treatment of dermatomycoses with topical tioconazole and miconazole. , 1983, Dermatologica.

[68]  R. Samson,et al.  Microscopic studies of Candida albicans and Torulopsis glabrata after in vitro treatment with bifonazole. Light and scanning electron microscopy. , 1983, Arzneimittel-Forschung.

[69]  H. Yamaguchi,et al.  In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole. , 1983, Arzneimittel-Forschung.

[70]  M. Tarbit,et al.  Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related to vaginal candidiasis. , 1983, Gynakologische Rundschau.

[71]  J. Artner,et al.  Double-blind comparison of the efficacy, tolerance and safety of tioconazole and placebo in patients with vaginal candidiasis and the assessment of systemic absorption. , 1983, Gynäkologisch-Geburtshilfliche Rundschau.

[72]  D. Barug,et al.  An evaluation of the antifungal effect of bifonazole on Torulopsis glabrata and Candida albicans under various in vitro test conditions. , 1983, Arzneimittel-Forschung.

[73]  M. Marriott,et al.  Inhibition of sterol C14 demethylation by imidazole-containing antifungals. , 1982, Sabouraudia.

[74]  S. Shadomy,et al.  A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. , 1982, Sabouraudia.

[75]  R. Hay,et al.  Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma , 1982, Clinical and experimental dermatology.

[76]  J. Faergemann,et al.  Tinea Versicolor: Some New Aspects on Etiology, Pathogenesis, and Treatment , 1982, International journal of dermatology.

[77]  K. Kuokkanen.  Topical tioconazole in dermatomycosis. , 1982, Mykosen.

[78]  I. Sud,et al.  Heterogeneity of action of mechanisms among antimycotic imidazoles , 1981, Antimicrobial Agents and Chemotherapy.

[79]  D. Feingold,et al.  Mechanisms of action of the antimycotic imidazoles. , 1981, The Journal of investigative dermatology.

[80]  F. Odds.  Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. , 1980, The Journal of antimicrobial chemotherapy.

[81]  M. Borgers.  Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. , 1980, Reviews of infectious diseases.

[82]  M S Marriott,et al.  Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. , 1980, Journal of general microbiology.

[83]  M. Leeming,et al.  Antifungal Activity of Tioconazole (UK-20,349), a New Imidazole Derivative , 1979, Antimicrobial Agents and Chemotherapy.

[84]  H. van den Bossche,et al.  Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. , 1978, Chemico-biological interactions.

[85]  D. Stevens.  Miconazole in coccidioidomycosis. , 1977, The Western journal of medicine.

[86]  J. Gentles.  Human and Animal Mycology , 1958, Nature.